homepage-top-section

Under the deal, Aurigene will receive $8m of upfront licensing payment for rights to the company’s pre-existing programme. The company will also be eligible for up to $60m

The antibody is indicated to treat R/R FL patients who have received at least two prior systemic therapies. Lunsumio is a CD20xCD3 T-cell engaging bispecific antibody that targets

The regulatory approval has been granted for the therapy to treat moderate-to-severe atopic dermatitis in children whose disease is not controlled with topical prescription therapies or when they

The approval will increase MMR vaccine choices in the US. Priorix (Measles, Mumps and Rubella Vaccine, Live) can be given as two doses. It can also be administered

According to a company statement, sugemalimab was approved for use on unresectable stage III NSCLC patients without disease progression after concurrent or sequential platinum-based chemoradiotherapy. NMPA approved sugemalimab

OrbiMed and Maruho have jointly led the financing round, which has also seen participation from HBM Healthcare Investments, Access Biotechnology, TCG X, Omega Funds, Decheng Capital, Samsara BioCapital,

The new investigational recombinant factor VIII (FVIII) therapy efanesoctocog alfa has been designed to extend protection from bleeds with once-weekly prophylactic dosing for haemophilia A patients. It is

New investor NexPoint led the financing round, which included participation from existing investors Eshelman Ventures, Bristol Myers Squibb, and Kingdon Capital. A convertible note, which was provided by

The companies are seeking approval for the antibody to treat adult patients with prurigo nodularis, which is a chronic inflammatory skin disease that causes extreme itch and skin